Ruxolitinib Shows Stronger Response in Primary Than Secondary HLH, Meta-Analysis Finds
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
A systematic review of 542 patients finds ruxolitinib-based regimens achieve an 87.2 percent overall response rate in hemophagocytic lymphohistiocytosis, with ...
A network meta-analysis of 28 randomized trials finds that internal radiation and brachytherapy approaches, including iodine-125 brachytherapy, IMRT, and iodine-131-metuximab, ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine